Literature DB >> 19279045

Metabolic features of the reproductive phenotypes of polycystic ovary syndrome.

Lisa Moran1, Helena Teede.   

Abstract

BACKGROUND Polycystic ovary syndrome (PCOS) is a common condition in women of reproductive age with well established metabolic abnormalities. There are numerous diagnostic criteria generating several reproductive diagnostic phenotypes [National Institute of Health (NIH) hyperandrogenic anovulatory PCOS and non-NIH PCOS including hyperandrogenic ovulatory or non-hyperandrogenic anovulatory PCOS]. There is ongoing debate regarding the optimal diagnostic criteria for PCOS and on the metabolic implications of newer non-NIH PCOS phenotypes. METHODS We reviewed the literature on the presence of risk factors for type 2 diabetes (DM2) and cardiovascular disease (CVD) across the reproductive diagnostic phenotypes of PCOS with the aims of comparing the metabolic features of the NIH and non-NIH groups and identifying potential high metabolic risk phenotypes of PCOS. RESULTS NIH PCOS patients present with greater obesity, abdominal obesity, insulin resistance (IR) and risk factors for DM2 and CVD compared with non-NIH ovulatory and non-hyperandrogenic PCOS patients. Where differences in metabolic features exist between the phenotypes, they are generally related to the degree of total and abdominal obesity. There is emerging evidence suggesting ovulatory and non-hyperandrogenic PCOS have greater metabolic abnormalities than controls primarily linked to abdominal adiposity. There is currently no evidence that non-hyperandrogenic PCOS is associated with a less adverse metabolic profile than ovulatory PCOS. CONCLUSIONS Current metabolic evidence appears to justify the inclusion of both non-NIH PCOS groups (ovulatory and non-hyperandrogenic) as PCOS subgroups. NIH PCOS is associated with a more adverse metabolic profile including greater total and abdominal obesity, IR and risk factors for CVD and DM2 than non-NIH phenotypes.

Entities:  

Mesh:

Year:  2009        PMID: 19279045     DOI: 10.1093/humupd/dmp008

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  88 in total

1.  C-Peptide, Baseline and Postprandial Insulin Resistance after a Carbohydrate-Rich Test Meal - Evidence for an Increased Insulin Clearance in PCOS Patients?

Authors:  J Stassek; J Erdmann; F Ohnolz; F D Berg; M Kiechle; V Seifert-Klauss
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-01       Impact factor: 2.915

Review 2.  The Role of Physical Activity in Preconception, Pregnancy and Postpartum Health.

Authors:  Cheryce L Harrison; Wendy J Brown; Melanie Hayman; Lisa J Moran; Leanne M Redman
Journal:  Semin Reprod Med       Date:  2016-05-11       Impact factor: 1.303

3.  Clomiphene citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial.

Authors:  Mohamad E Ghanem; Laila A Elboghdady; Mohamad Hassan; Adel S Helal; Ahmed Gibreel; Maha Houssen; Mohamed E Shaker; Ibrahiem Bahlol; Yaser Mesbah
Journal:  J Assist Reprod Genet       Date:  2013-09-07       Impact factor: 3.412

4.  Metabolic implications of menstrual cycle length in non-hyperandrogenic women with polycystic ovarian morphology.

Authors:  Miro Šimun Alebić; Nataša Stojanović; Dinka Pavičić Baldani; Lea Smirčić Duvnjak
Journal:  Endocrine       Date:  2016-08-03       Impact factor: 3.633

5.  Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria.

Authors:  Miro Šimun Alebić; Tomislav Bulum; Nataša Stojanović; Lea Duvnjak
Journal:  Endocrine       Date:  2014-02-13       Impact factor: 3.633

Review 6.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

7.  Rapid and easy assessment of insulin resistance contributes to early detection of polycystic ovary syndrome.

Authors:  M Rizzo; E K Tyndall; S Frontoni; F Jacoangeli; F Sarlo; F Panebianco; A Mistorni; L Di Renzo; R Calafiore; G Luca; A De Lorenzo
Journal:  J Endocrinol Invest       Date:  2013-04-23       Impact factor: 4.256

8.  Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Adiposity and Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep.

Authors:  Rodolfo C Cardoso; Almudena Veiga-Lopez; Jacob Moeller; Evan Beckett; Anthony Pease; Erica Keller; Vanessa Madrigal; Gregorio Chazenbalk; Daniel Dumesic; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2015-12-09       Impact factor: 4.736

9.  Genetic variants of the HSD11B1 gene promoter may be protective against polycystic ovary syndrome.

Authors:  Vince Kornél Grolmusz; Orsolya Dóra Acs; Karolina Feldman-Kovács; Ágnes Szappanos; Balázs Stenczer; Tibor Fekete; György Szendei; Péter Reismann; Károly Rácz; Attila Patócs
Journal:  Mol Biol Rep       Date:  2014-06-27       Impact factor: 2.316

Review 10.  Nonhuman primate models of polycystic ovary syndrome.

Authors:  David H Abbott; Lindsey E Nicol; Jon E Levine; Ning Xu; Mark O Goodarzi; Daniel A Dumesic
Journal:  Mol Cell Endocrinol       Date:  2013-01-29       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.